本期信息
瑋俊生物科技有限公司公布截至2025年12月31日止六个月的中期业绩，报告期内实现营收3.52亿元港币，同比增加118.7%。毛利约0.36亿元港币，较上年同期约0.21亿元港币提高约68.8%，但毛利率从13.1%下降至10.1%。
期间经调整净亏损约0.06亿元港币，较上年同期约0.14亿元港币的亏损有所减少。管理层指出，销售费用约0.15亿元港币，同比上升181.9%；行政费用约0.15亿元港币，同比上升22.8%。财务成本则由上年同期约0.10亿元港币降至约0.05亿元港币，主要由于相关债务条款变化带来的利息支出减少。
成本结构方面，销售成本达到3.16亿元港币，较上年同期约1.40亿元港币有所增加，主要是因市场需求增长带来的产销量上升所致。销售及管理费用率也在营收增长背景下出现一定幅度上升。
本公司将继续探索潜在并购及投资机会，以期在后续期间进一步拓展收入来源并优化成本结构。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.